Zynex Continues Fight Against Opioid Abuse and Expands Its Arsenal of Pain Relief Products

  Zynex Continues Fight Against Opioid Abuse and Expands Its Arsenal of Pain
                               Relief Products

PR Newswire

LONE TREE, Colo., Sept. 18, 2017

LONE TREE, Colo., Sept. 18, 2017 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an
innovative medical technology company specializing in the manufacture and sale
of non-invasive medical devices for pain management, stroke rehabilitation,
cardiac monitoring and neurological diagnostics.  The company continues to
introduce several new products to its product portfolio in its efforts to
address the pain and rehabilitation markets and the current opioid epidemic.


Given American's current crisis with opioid addiction, Zynex is committed to
providing health care professionals a variety of prescription-strength options
without side-effects. This has never been more necessary than it is today
considering the staggering statistics. 

  o Pain impacts the lives of more Americans than diabetes, heart disease and
    cancer combined.
  o Pain is the leading cause of disability and the most common reason
    American's seek health care is because they are seeking treatment for
    acute or chronic pain.
  o 1 in every 4 Americans (76.2 million people), suffer with pain that lasts
    longer than 24 hours.
  o Approximately 25.3 million adults struggle with chronic pain, pain every
    day that has been present for more than 3 months.
  o If pharmaceuticals such as opioids continue to be used as the first line
    of defense America will continue to see a rise in opioid misuse, addiction
    and drug-related deaths.

Aware of the current issues, Zynex has a dedicated team working to expand the
product line beyond electrotherapy alone. Zynex has added new products such as
JetStream Hot/Cold Therapy, Aspen LSO Backbracing and Comfortrac cervical
traction, all products targeted at treating acute as well as chronic pain
without side-effects.  

Zynex is committed to making prescription strength drug-free options more
accessible to patients and easier for physicians to prescribe as a first line
defense rather than prescribing opioid pharmaceuticals.

Thomas Sandgaard, Founder and CEO commented: "Our prescription-strength
NexWave device is already available nationwide and I am excited that we are
now able to offer traction, low back support and cold/hot therapy as an
effective alternative for physicians to prescribe for patients with severe

I strongly believe that any effort to provide opioid free treatment can
improve the lives of millions of Americans living with pain, slow down the too
frequent path to addiction and hopefully save many lives. We are currently
experiencing a horrific epidemic in this country and I am committed to be part
of a healthy solution to the problem.   

As we continue to expand our sales force and increase our presence across the
country, all of these products will become more accessible. In an effort to
provide more details about Zynex prescription-strength products, we are
developing a National Webcast service designed to educate health care
providers on our product line and the ease of prescribing. Our EZ-Rx program
makes it easy for physicians everywhere in the U.S. to offer drug-free
solutions to their efforts of pain management."

About Zynex 

Zynex, founded in 1996, markets and sells its own design of electrotherapy
medical devices used for pain management and rehabilitation; and the company's
proprietary NeuroMove device designed to help recovery of stroke and spinal
cord injury patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers, a non-invasive device to monitor fluid
imbalance. For additional information, please visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are
subject to numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such statements.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the need to obtain
additional capital or augment our liquidity in order to continue our business,
the success of our international expansion efforts, our ability to engage
additional sales representatives and their success, the need to obtain FDA
clearance and CE marking of new products, the acceptance of new products as
well as existing products by doctors and hospitals, larger competitors with
greater financial resources, the need to keep pace with technological changes,
our dependence on the reimbursement from insurance companies for products sold
or rented to our customers, acceptance of our products by health insurance
providers, our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales strategy including
a strong direct sales force, the uncertain outcome of pending material
litigation, our ability to up-list to a larger exchange and other risks
described in our filings with the Securities and Exchange Commission including
the "Risk Factors" section of our Annual Report on Form 10-K for the year
ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases
and the Company's website.

Contact: Zynex, Inc.  (303) 703-4906
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel


View original content with


Website: http://www.zynexmed.com
Press spacebar to pause and continue. Press esc to stop.